loading
Aclaris Therapeutics Inc stock is traded at $1.26, with a volume of 404.33K. It is up +0.00% in the last 24 hours and up +5.88% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$1.26
Open:
$1.25
24h Volume:
404.33K
Relative Volume:
0.48
Market Cap:
$136.43M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-2.4231
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
-3.82%
1M Performance:
+5.88%
6M Performance:
-66.84%
1Y Performance:
+6.78%
1-Day Range:
Value
$1.22
$1.285
1-Week Range:
Value
$1.22
$1.38
52-Week Range:
Value
$0.9515
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Name
Aclaris Therapeutics Inc
Name
Phone
484-324-7933
Name
Address
701 LEE ROAD, WAYNE, PA
Name
Employee
64
Name
Twitter
@aclaristx
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
1.26 141.85M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-18-25 Resumed Cantor Fitzgerald Overweight
Dec-23-24 Upgrade H.C. Wainwright Neutral → Buy
Nov-20-24 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-19-24 Upgrade BTIG Research Neutral → Buy
Nov-19-24 Upgrade Jefferies Hold → Buy
Nov-19-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-18-24 Upgrade Piper Sandler Neutral → Overweight
Jan-22-24 Downgrade H.C. Wainwright Buy → Neutral
Nov-13-23 Downgrade William Blair Outperform → Mkt Perform
Oct-03-23 Initiated Evercore ISI Outperform
Dec-14-22 Initiated Stifel Buy
Dec-01-22 Initiated Goldman Buy
Oct-06-22 Initiated BTIG Research Buy
Jul-23-21 Resumed Jefferies Buy
Jun-15-21 Initiated Piper Sandler Overweight
Apr-21-21 Initiated H.C. Wainwright Buy
Oct-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19 Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19 Initiated SVB Leerink Outperform
Mar-28-18 Resumed Leerink Partners Outperform
Feb-09-18 Initiated Guggenheim Buy
Jun-16-17 Initiated Cantor Fitzgerald Overweight
Nov-29-16 Initiated Leerink Partners Outperform
Sep-30-16 Initiated JMP Securities Mkt Outperform
Jun-10-16 Initiated Guggenheim Buy
Nov-02-15 Initiated Citigroup Buy
Nov-02-15 Initiated Jefferies Buy
View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

pulisher
May 21, 2025

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World

May 21, 2025
pulisher
May 18, 2025

HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World

May 17, 2025
pulisher
May 16, 2025

Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN

May 16, 2025
pulisher
May 16, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World

May 16, 2025
pulisher
May 14, 2025

Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN

May 14, 2025
pulisher
May 13, 2025

Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com

May 13, 2025
pulisher
May 12, 2025

Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN

May 12, 2025
pulisher
May 12, 2025

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN

May 12, 2025
pulisher
May 11, 2025

Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World

May 11, 2025
pulisher
May 10, 2025

Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Purchases New Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 10, 2025
pulisher
May 10, 2025

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire

May 10, 2025
pulisher
May 10, 2025

Scotiabank Adjusts Price Target for Aclaris Therapeutics (ACRS) - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Aclaris Therapeutics to Participate in the HC Wainwright 'HCW@Home” Series - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire Inc.

May 09, 2025
pulisher
May 09, 2025

Mariner LLC Sells 10,327 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 09, 2025
pulisher
May 09, 2025

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 09, 2025
pulisher
May 09, 2025

Aclaris: Q1 Earnings Snapshot - CT Insider

May 09, 2025
pulisher
May 08, 2025

Aclaris Therapeutics Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com India

May 08, 2025
pulisher
May 08, 2025

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Aclaris Therapeutics Reports Q1 2025 Financial Results and Corporate Update with Focus on Immuno-Inflammatory Developments and Extended Cash Runway through 2028 - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Hims & Hers Has a Superpower in Healthcare - The Globe and Mail

May 08, 2025
pulisher
May 08, 2025

Here's Why I'm Still Buying SoFi Hand Over Fist in 2025 - The Globe and Mail

May 08, 2025
pulisher
May 07, 2025

Aclaris Therapeutics Inc (ACRS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX

May 07, 2025
pulisher
May 06, 2025

Invesco Ltd. Invests $28,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 06, 2025
pulisher
May 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World

May 04, 2025
pulisher
Apr 30, 2025

Geode Capital Management LLC Reduces Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 30, 2025
pulisher
Apr 30, 2025

XTX Topco Ltd Acquires New Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 30, 2025
pulisher
Apr 30, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 29, 2025

Aclaris Therapeutics Names Jesse Hall Chief Medical Officer - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Aclaris Therapeutics (ACRS) Welcomes Jesse Hall as Chief Medical Officer | ACRS Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Aclaris Therapeutics appoints new Chief Medical Officer - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Aclaris Strengthens Leadership: Humira and Prolia Developer Takes CMO Role to Advance Immunology Pipeline - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Androgenetic Alopecia Treatment Market Generated - openPR.com

Apr 29, 2025
pulisher
Apr 26, 2025

Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Apr 26, 2025

Aclaris Therapeutics Inc Stock (ACRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
Cap:     |  Volume (24h):